Clinical Value of Circulating ZFAS1 and miR-590-3p in the Diagnosis and Prognosis of Chronic Heart Failure

Author(s):  
Guannan Chang ◽  
Wenqing Zhang ◽  
Meicheng Zhang ◽  
Gang Ding
2015 ◽  
Vol 31 (4) ◽  
pp. 535-544 ◽  
Author(s):  
Shinpei Kadowaki ◽  
Tetsuro Shishido ◽  
Yuki Honda ◽  
Taro Narumi ◽  
Yoichiro Otaki ◽  
...  

2007 ◽  
Vol 18 (4) ◽  
pp. 425-433 ◽  
Author(s):  
ROBERTO MAESTRI ◽  
GIAN DOMENICO PINNA ◽  
AGOSTINO ACCARDO ◽  
PAOLO ALLEGRINI ◽  
RITA BALOCCHI ◽  
...  

Author(s):  
R. Trofimjak ◽  
L. Slivinska

The present study was undertaken to evaluate if any signifi cant hematological and biochemical changes occur in dogs with chronic heart failure (CHF), that will help in the diagnosis and prognosis of CHF. According to the obtained data, neutrophil leukocytosis was found in 22.2% of the animals in the experimental group, and anemia was found in 50.0%. Among them the 77,8 % of animals had nonregenerative anemia, the 77,8 % – hypochromic anemia, 38,9 % of – microcytic anemia. Neutrophil leukocytosis was registered in dogs with regenerative shift of the nucleus to the left (13.8%) and to the right (5.6%), and without changes in the leukogram (2.8%). It should be noted that 55.6% of animals with signs of CHF were also diagnosed with changes in the ratio of segmented neutrophils (degenerative shift of the nucleus to the left) in the absence of leukocytosis. Hypoproteinemia was found in 8,3% of animals, hypoalbuminemia in 13,8%, urea and creatinine concentrations were increased in 16,7 % and 19,4%, respectively. Hypocalcaemia was observed in 5,6% of dogs, inorganic phosphorus content was higher in 13,9%, slight hyponatremia was observed in 19,4%. The activity of enzymes in the serum of dogs in the experimental group ranged widely and was higher in ALT (p <0.001), AST (p <0.05), ALP (p <0.001), GGTP (p <0.01) compared with the control group.In the experimental group of 36 animals in 22,2 % of dogs were diagnosed cholestasis, in 22,2 % – hepatopathy, in 11,1 % – chronic kidney disease, and 8,3% –enteropathy, 5,5 % – paraneoplastic syndrome. Biochemical analysis of blood in dogs with signs of CHF is relevant, because it allows to diagnose comorbidities that may worsen the prognosis in these animals, and their timely detection and correction will increase the eff ectiveness of treatment. Key words: chronic heart failure, dog, hematology analysis, anemia, leukocytosis, hypoalbuminemia, renal failure,cholestasis, hepatopathy.


2018 ◽  
Vol 8 (5) ◽  
pp. 333-345
Author(s):  
A. M. Aliyeva ◽  
E. V. Reznik ◽  
E. T. Hasanova ◽  
I. V. Zhbanov ◽  
I. G. Nikitin

Biomarkers (various laboratory biochemical markers), such as natriuretic peptides (NP), soluble ST2 receptor, copeptin, galectin-3, are widely studied in patients with chronic heart failure (CHF). The European Society of Cardiology recommends the determination of blood NP level in suspicion of HF and its use as one of the mandatory diagnostic criteria for CHF with preserved and mid-range ejection fraction. Dynamics of NP concentration may be predictor of the effectiveness of the therapy and the necessity of the titration of the dose of HF drugs. Neprilyzin destroys NP, but does not destroy their precursors, including NT-proBNP. Therefore, it is necessary to use NT-proBNP as a marker of therapeutic efficacy and prognosis when using neprilysine inhibitors (sacubitril). ST2 is a protein receptor for interleukin-33 (IL-33). The transmembrane ST2 (ST2L) binds to IL-33 and forms the IL-33/ST2L complex, which has a cardioprotective effect, prevents the development of myocardial hypertrophy, fibrosis and apoptosis. The soluble ST2 receptor (sST2) is a “trap” for IL-33 and neutralizes the protective effects of the IL-33/ST2L complex, which leads to hypertrophy and fibrosis of the myocardium, dilatation of the chambers and reduction of the contractility of the heart. It can be considered as a marker of unfavorable prognosis in heart failure, but it is not specific. Copeptin is a part of the arginine-vasopressin, or antidiuretic hormone, precursor which plays an important role in the pathogenesis of CHF. Since arginine-vasopressin has a short half-life and is unstable outside the body, copeptin is being actively investigated. Its level increases during the CHF decompensation and relates with the functional class of CHF. A combined measurement of the concentration of copeptin and NP may improve the risk stratification in CHF patients. Galectin-3 is a peptide that stimulates the activation of fibroblasts and the development of fibrosis. It increases in CHF patients and is associated with the severity of the condition, systolic and diastolic LV dysfunction and prognosis. Currently, NP are the best biomarkers that can and should be used in routine clinical practice. To prove the need for widespread use of other biomarkers, additional research is needed.


2012 ◽  
Vol 18 (10) ◽  
pp. S179
Author(s):  
Yasuhiko Mitsuke ◽  
Akira Nakano ◽  
Hiroyasu Uzui ◽  
Naoki Amaya ◽  
Kentaroh Ishida ◽  
...  

2019 ◽  
Vol 5 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Hans-Peter Brunner-La Rocca ◽  
Sandra Sanders-van Wijk

Normal brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels are helpful in excluding chronic heart failure in the ambulatory setting, although they have been studied less well and possibly less accurately than in acute care. They may also be of help in screening patients at risk to intervene and reduce the development of heart failure. Natriuretic peptides are also excellent prognostic markers of chronic heart failure, but the clinical value of such prognostic information is less clear. One possible application for this information is guiding medical therapy in chronic heart failure. Many studies have investigated this approach, but results are mixed and do not clearly show improvement in outcome. Still, it may be that in patients with reduced ejection fraction and few comorbidities, measuring NT-proBNP to uptitrate medication improves prognosis.


2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Francesco Gentile ◽  
Alberto Aimo ◽  
James Lj Jannuzzi ◽  
Mark Richards ◽  
Carolyn Sp Lam ◽  
...  

Abstract Aims Limited evidence exists on sex-related differences in clinical value of biomarkers in chronic heart failure (HF). We aimed to define plasma levels, determinants, and optimal prognostic cut-offs of soluble suppression of tumourigenesis-2 (sST2), high-sensitivity troponin T (hs-TnT), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in female and male chronic HF patients. Methods and results Individual data of patients from the BIOS (Biomarkers In Heart Failure Outpatient Study) Consortium with sST2, hs-TnT, and NT-proBNP measured were analysed. The primary endpoint was a composite of 1-year cardiovascular death and HF hospitalization. The secondary endpoints were 5-year cardiovascular and all-cause death. The cohort included 4540 patients (age: 67 ± 12 years, LVEF 33 ± 13%, 1111 women, 25%). Women showed lower sST2 (24 vs. 27 ng/ml, P &lt; 0.001) and hs-TnT level (15 vs. 20 ng/l, P &lt; 0.001), and similar concentrations of NT-proBNP (1540 vs. 1505 ng/l, P = 0.408). Although the three biomarkers were confirmed as independent predictors of outcome in both sexes, the optimal prognostic cut-off was lower in women for sST2 (28 vs. 31 ng/ml) and hs-TnT (22 vs. 25 ng/l), while NT-proBNP cut-off was higher in women (2339 ng/l vs. 2145 ng/l). The use of sex-specific cut-offs improved risk prediction compared to the use of previously standardized prognostic cut-offs (Figure). Conclusions In patients with chronic HF, levels of sST2 and hs-TnT, but not of NT-proBNP are lower in women. Lower sST2 and hs-TnT and higher NT-proBNP cut-offs for risk stratification could be used in women.


2010 ◽  
Vol 16 (9) ◽  
pp. S156
Author(s):  
Takehiko Sato ◽  
Yasuhiko Mitsuke ◽  
Tetsuji Morishita ◽  
Tohru Geshi ◽  
Akira Nakano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document